Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus DPI, Clontech Laboratories

Premium
BioFocus DPI this week launched a drug-discovery service called PrimePath, which screens small molecules using disease-relevant human primary cells.
 
Clients will have the opportunity to screen compounds against cellular disease models that have already been developed by BioFocus and are available “off the shelf,” the company said. BioFocus said that it can also work with clients to develop new cellular disease models that mimic a specific disease process for a defined therapeutic area.
 

 
Clontech Laboratories this week announced that it is making the DsRed-monomer fluorescent protein available to for-profit entities for research and commercial use. Previously, Ds-Red was only available to not-for-profit institutions.
 
Ds-Red monomer is a highly engineered monomeric form of the normally tetrameric Discosoma sp. red fluorescent protein, and is part of Clontech’s Living Colors line of fluorescent proteins. The red-shifted emission spectra and monomeric form of Ds-Red makes it ideal as a fusion tag, Clontech said.
 

 
Note: A number of new cell-based assay products were released at the Society for Biomolecular Sciences annual meeting held this week in Seattle, but could not be included in this issue due to time constraints. Look in next week’s issue of CBA News for a full product roundup from the show.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.